Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 5,11 € (+340,52 %). Medianen er 4,99 € (+330,17 %).
| Køb |
16 |
| Behold |
13 |
| Sælg |
2 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Fate Therapeutics presents progress on autoimmune CAR-T: master cell bank and FT819 in focus
Fate Therapeutics showcased its master cell bank platform at the Cantor conference, which the company says could enable more than 10 million doses and reduce production costs to about $3,000 per dose. The lead program is FT819 for lupus nephritis; early data show pronounced UPCR reductions and management reports alignments with the FDA for a registration‑enabling phase II study. FT839 (CD19/CD38) received IND clearance and first patient treatment is expected in a few months. The company emphasizes a favorable safety profile in nearly 100 treated patients but sees execution risks from long timelines and competition. » Mere på de.investing.com
Fate Therapeutics presents promising preliminary FT819 data in systemic sclerosis
Fate Therapeutics presented preliminary clinical data on its allogeneic CAR‑T candidate FT819 at the annual meeting of the International Society for Stem Cell Research, focusing on the systemic sclerosis arm of the ongoing phase‑1 basket study. All of the first four patients treated between June 4 and 12 achieved a CRISS ≥25 at three months and showed improvements in the modified Rodnan skin score, with no reports of cytokine release syndrome, ICANS, GvHD, hypogammaglobulinemia, or deaths. FT819 is also being investigated in systemic lupus and is planned for a phase‑2 study in lupus nephritis. Fate Therapeutics is trading near its 52‑week high, has a market capitalization of about $340 million, and remained financially flexible despite cash burn of roughly $108 million. » Mere på de.investing.com
Fate Therapeutics presents CAR‑T data at ASCO and European Congress of Rheumatology
Fate Therapeutics will present data on three CAR‑T candidates at specialist conferences in late May/early June: preliminary Phase‑1 results for FT836 at the ASCO meeting, safety/efficacy data for FT819 and an oral presentation on FT839 at the European Congress of Rheumatology. The company is developing iPSC‑derived, “off‑the‑shelf” cellular immunotherapies. Investors should note that Fate is burning cash quickly, remains unprofitable, but the stock has risen sharply since the start of the year. » Mere på de.investing.com
Fate Therapeutics presents new CAR-T data at ASGCT meeting
At the ASGCT annual meeting, Fate Therapeutics presented clinical data on FT819 in systemic lupus erythematosus: three patients who received a single dose without conditioning showed SRI-4 responses and two achieved LLDAS; B-cell depletion persisted for up to 12 months, and a higher dose of 900 million cells has been initiated. Preclinical data for FT839 (dual targeting CD19/CD38) showed >99% depletion of B cells, plasmablasts and plasma cells and high selectivity versus activated T cells. FT836 demonstrated tumor control in xenograft models as both monotherapy and in combination, and radiation and chemotherapy increased MICA/B expression and cytolytic activity. The company remains unprofitable but has a cash surplus and a market capitalization of about $278 million. » Mere på de.investing.com
FDA accepts FT819 from Fate Therapeutics into pilot program for CMC development
The FDA has selected Fate Therapeutics’ CAR-T therapy FT819 for its pilot program to develop and prepare chemistry, manufacturing and controls (CDRP). FT819 is an off-the-shelf CD19‑CAR‑T candidate for the treatment of moderate to severe systemic lupus erythematosus and already holds RMAT designation. Participation in the program is intended to intensify communication with the FDA and clarify CMC questions; FT819 is designed for outpatient use with same‑day discharge. Investors reacted positively: the stock rose sharply last week, but the company remains unprofitable according to analysis. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | 100,00 % |
| Bruttofortjeneste | -2,36 mio. | 88,49 % |
| Nettoresultat | -27,09 mio. | 1,42 % |
| EBITDA | -26,1 mio. | 5,55 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 135,41 mio. € |
Antal aktier | 116,56 mio. |
Højeste/laveste i 52 uger | 2,93 € - 0,86 € |
| Udbytte | Nej |
Beta | 2,67 |
P/E (PE Ratio) | -1,24 |
PEG (PEG Ratio) | -0,05 |
K/I (PB Ratio) | 1,19 |
P/S (PS Ratio) | 31,41 |
Virksomhedsprofil
Fate Therapeutics, Inc. er et klinisk-stadie biofarmaceutisk selskab, der udvikler programmerede cellulære immunterapier mod kræft og immunsygdomme på verdensplan. Selskabets NK- og T-celle immunonkologiske programmer under udvikling omfatter FT516 til behandling af akut myeloid leukæmi (AML), B-celle lymfom og avanceret solid tumor; FT596 til behandling af B-celle lymfom og kronisk lymfocytisk leukæmi; FT538 til behandling af AML og multipelt myelom; FT576 til behandling af multipelt myelom; FT819 til behandling af hæmatologiske maligniteter og solide tumorer; FT536 til behandling af solide tumorer; og FT500 til behandling af avancerede solide tumorer. Selskabet har en samarbejds- og optionsaftale med Ono Pharmaceutical Co. Ltd. om udvikling og kommercialisering af to off-the-shelf iPSC-afledte CAR T-celle produktkandidater; en strategisk forskningssamarbejds- og licensaftale med Juno Therapeutics, Inc. om screening for og identifikation af småmolekylære modulatorer, der forbedrer de terapeutiske egenskaber ved genetisk modificerede T-celle immunterapier; og en samarbejds- og optionsaftale med Janssen Biotech, Inc. Fate Therapeutics, Inc. blev stiftet i 2007 og har hovedkontor i San Diego, Californien.
| Navn | Fate Therapeutics |
| CEO | Bahram Valamehr |
| Hjemsted | San Diego,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 01.10.2013 |
| Medarbejdere | 161 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | FATE |
Frankfurt | F6T.F |
Düsseldorf | F6T.DU |
München | F6T.MU |